Search results for "Phase 3 trial"

Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27

Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27

Samsung Bioepis announced on Aug. 10 that it has submitted a marketing authorization application to South Korea's Ministry of Food and Drug Safety...
Hanmi Control Dispute Reignites as Court Freezes 10 Billion Won in Lim Ju-hyun’s Shares

Hanmi Control Dispute Reignites as Court Freezes 10 Billion Won in Lim Ju-hyun’s Shares

The "four-party alliance" formed to stabilize management control at Hanmi Pharmaceutical Group has descended into open legal warfare, with major...
HK inno.N's K-CAB Secures Sixth Indication to Prevent Ulcers from Long-Term NSAID Use

HK inno.N's K-CAB Secures Sixth Indication to Prevent Ulcers from Long-Term NSAID Use

HK inno.N’s gastroesophageal reflux disease drug K-CAB has expanded its approved uses to include the prevention of...
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia

Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia

OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C...
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE.
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short

Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short

Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition

GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition

A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market

Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market

The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Celltrion Secures South Korean Phase 1 Approval for Tremfya Biosimilar CT-P68

Celltrion Secures South Korean Phase 1 Approval for Tremfya Biosimilar CT-P68

Celltrion announced on July 15 that it has received approval from South Korea’s Ministry of Food and Drug Safety for an...